

# Differential Expression of Ago2-Mediated MicroRNA Signaling in Adipose Tissue is Associated with Food Induced Obesity

**Hansi Zhang**

Xinxiang Medical University

**Liang Qiao**

Xinxiang Medical University

**Xiaoxuan Liu**

Xinxiang Medical University

**Xiaojing Han**

Xinxiang Medical University

**Jing Kang**

Xinxiang Medical University

**Yanli Liu**

Xinxiang Medical University

**Juntang Lin**

Xinxiang Medical University

**Xin Yan** (✉ [xin.yan@xxmu.edu.cn](mailto:xin.yan@xxmu.edu.cn))

Xinxiang Medical University

---

## Research Article

**Keywords:** RNA-binding proteins, microRNAs, energy homeostasis, obesity, adipose tissue

**Posted Date:** February 16th, 2022

**DOI:** <https://doi.org/10.21203/rs.3.rs-1355723/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

**Background:** Obesity is strongly linked to the dysregulation of adipose tissues. Previous studies have reported that the roles of Ago2 mediated microRNA signaling in the regulation of metabolic homeostasis and obesity. However, it is unclear whether this function extends to in adipose tissue. Here we sought to further understand the role of Ago2 in the adiposity during obesity.

**Methods:** We first analyzed the food induced obese mouse models for alterations in body weight, glucose and energy homeostasis, subsequently characterized the expression of Ago2-miR148-AMPK $\alpha$  signaling pathway. Finally, hematoxylin and eosin staining was performed to analyze the morphological changes in adipose pads and liver.

**Results:** Here we show that high-fat diet feeding mice exhibited an increase in body mass alongside systematic insulin resistance and altered rate of energy expenditure. Interestingly, Ago2 expression is associated with obesity and increased in adipose tissues. Moreover, increase of Ago2 inhibited the expression of AMPK $\alpha$  by promoting its targeting by miR-148a, the most abundant microRNA in the adipose tissues.

**Conclusion:** Those results suggested that *Ago2-miR-148a-AMPK $\alpha$*  signaling pathway play an important function in the developing obesity and adiposity and will further provide basic research data for the potential clinic treatment of obesity.

## 1. Background

Obesity is a chronic progressive disease and characterized by energy imbalance resulting from excessive calorie intake and abnormal energy expenditure [1]. Generally, it's associated with type 2 diabetes, insulin resistance and inflammation [2, 3]. As the prevalence of the disease continues to increase worldwide, it remains imperative to identify novel genes and their pathways that contribute to obesity. Recent studies have shown that several tissue specific microRNAs (miRNA) contributed to the progression of obesity, dissecting their mechanism of action in vivo still remain a challenge.

The Argonaute 2 (Ago2) is a core component of RNA-induced silencing complex (RISC) and can mediate miRNA to interact with target mRNA [4, 5]. Interestingly, Ago2 related miRNA pathway is emerging as an important contributor in several tissues and essential to regulate glucose metabolism and cellular energy homeostasis [6-9]. For example, Ago2 is considered to be an important regulator of liver energy metabolism and high-fat diet feeding forces liver to express excessive Ago2 in liver [8]. Conditional deletion of Ago2 in liver can improve the glucose metabolism through the activation of AMPK signaling pathway during high-fat diet (HFD) feeding [8, 9]. Furthermore, obesity significantly increases the expression of Ago2 in islets, giving rise to pancreatic  $\beta$ -cell proliferation and insulin resistance, which further provide evidence for Ago2 in the regulation of cellular metabolism [6].

Adipose tissues have an important function in sensing and managing energy status through lipid storage and release, and adipokines secretion [10, 11]. Strongly accumulation of excess visceral adiposity can cause obesity which is associated with different metabolic dysfunction including chronic inflammation [11, 12]. Several studies have reported that many miRNAs in adipose tissues including *miR-34a*, *miR-93*, *miR-106*, *miR-148a*, *miR-221* have been shown to affect adipogenesis and adiposity [13-17]. For example, *miR-93* has been shown to control adipocyte differentiation by negatively regulating *Tbx3*, loss of *miR-93* results in increased fat mass and insulin resistance [14]. Furthermore, *miR-148a* is required for the adipocyte differentiation and highly increased in the epididymal adipose tissue of mice after HFD feeding [15]. These results provide strong evidence for the miRNA pathway in regulating cellular energy metabolism in the adipose tissues.

Several studies have shown that tissue specific Ago2 and its mediated miRNA signaling pathways play a crucial role on body metabolism and contribute to the progression of obesity. However, it is unclear whether this function extends to other tissues, especially in adipose tissue. Therefore, current study will investigate the role of Ago2 in fat tissues. We find that HFD-induced obesity is defined by the metabolic dysregulation and disrupted energy homeostasis, and that these changes are largely associated with the evaluated expression of Ago2 in different adipose depots. The increased Ago2 led to a concomitant upregulation of *miR-148a* and downregulation in AMPK expression in adipose tissues. Finally, histological analysis and thermogenesis genes were performed to assess their relationships to HFD-induced changes in miRNA signaling pathway. Together, those results demonstrate Ago2 as an important regulator in physiological processes of adipose tissues and further reinforce the role of Ago2-mediated miRNA signaling in regulation of HFD-induced obesity.

## 2. Materials And Methods

### Animals model

All animals maintained on a 12 h light/dark cycle. To obtain high fat diet induced obesity model, C57/BL6J mice (6 weeks old) were randomly assigned to two groups. Then, the mice were fed either normal chow diet (Chow) with 10 KJ% fat (Keao Xieli, Beijing) as control group, or high fat diet (HFD) with 60 KJ% fat (Keao Xieli, Beijing) as obesity group *ad libitum* until 16 weeks. All experimental procedures and protocols were approved by the Animal Research Committee of Xinxiang Medical University according to the Chinese Council on Animal Care guidelines.

### Body weight and composition analysis

Body weights were measured every week with a digital scale. Body composition of lean body mass (LBM) and fat mass were measured using time-domain nuclear magnetic resonance (TD-NMR) method (the minispec Live Mice Analyzer LF90, Bruker).

### Analysis of glucose metabolism in mice

Blood samples were collected from submandibular vein and centrifuged at 2000 g for 10 min. Plasma insulin and leptin were measured by commercial enzyme-linked immunosorbent assay (ELISA) kit (Crystal Chem Inc. #90080, #90030). Plasma triglyceride, free fat acid (FFA), glycerol, and cholesterol levels were measured using commercially available kits (Cayman, 10010303, 700310, 10010755, 10007640).

For glucose tolerance test (GTT), mice were injected intraperitoneally (i. p.) with D-glucose (2 mg/g body weight) after overnight fasting, blood glucose levels were measured using Glucometer (Contour, Bayer) before and following the injection from the facial vein of non-anesthetized animals. For insulin tolerance test (ITT), 6 h fasted mice were injected by i. p. with human recombinant insulin (0.75 U/kg body weight, PAN Biotech), and tail-tip blood glucose was measured before and after the injection.

### **Metabolic Phenotyping analysis**

Sixteen weeks old Chow and HFD mice were acclimated into home cage of Promethion Core System (Sable Systems International) for 24 h before the start of the experimental record. Then, O<sub>2</sub> and CO<sub>2</sub> exchange were continuously recorded every 9 min for 1 min for 4 days, and locomotor activity was continuously recorded by interruptions of infrared light beams. O<sub>2</sub> consumed (VO<sub>2</sub>), CO<sub>2</sub> produced (VCO<sub>2</sub>), and energy expenditure (EE) were calculated following the manufacturer's manual, and the respiratory exchange ratio (RER) was computed by the ratio of VCO<sub>2</sub>/VO<sub>2</sub>. Finally, EE was analyzed either after the normalization by LBM or locomotor activity using covariance (ANCOVA).

### **Western blot**

Total protein of brown adipose tissue (BAT), subcutaneous white adipose tissues (sWAT), and epididymal white adipose tissues (eWAT) were lysed by RIPA buffer, and quantitated by Pierce™ BCA Protein Assay kit (23225, ThermoFisher Scientific). Equal amounts of protein (20 µg) were separated by SDS-PAGE electrophoresis, transferred to PVDF membrane, and blocked in 5% skim milk in TBST. Then, the membrane was incubated overnight with primary antibody solution at 4 °C. After rinsing the blot, the membrane was incubated in the horseradish peroxidase (HRP)-conjugated secondary antibody solution for 2 h at room temperature. Finally, chemiluminescent signals on the blot were applied with SuperSignal™ West Femto Maximum Sensitivity Substrate (34095, ThermoFisher Scientific), and captured using Amersham Imager 600 imagers (GE Healthcare Life Sciences). The band intensity of protein was read by image analysis software Fiji. The following primary and secondary antibodies were used in this study: Ago2 (RN003M, MBL International, 1:1000), UCP1 (#14670, Cell Signaling Technology, 1:1000), AMPKα (#2532, Cell Signaling Technology, 1:1000), p-AMPKα (#2535, Cell Signaling Technology, 1:1000), GAPDH (ab8245, Abcam, 1:1000), Goat Anti-Rabbit IgG H&L (HRP) (ab6721, Abcam, 1:10000), Goat Anti-Mouse IgG H&L (HRP) (ab6789, Abcam, 1:10000).

### **Quantitative real-time polymerase chain reaction (qPCR)**

Total RNA was isolated from BAT, sWAT, eWAT and inguinal white adipose tissue (ingWAT) using RNeasy plus Mini kit (QIAGEN) and quantitated by Spark<sup>®</sup> (TECAN). First strand cDNA from total RNA was efficiently synthesized using RevertAid First Strand cDNA Synthesis Kit (#K1621, ThermoFisher Scientific). Quantitation of *miR-148a-3p* expression level was performed with TaqMan<sup>™</sup> MicroRNA Assay (4440887, Applied Biosystems) and normalized to U6 snRNA following the primers from Applied Biosystems: *mmu-miR-148a-3p* (mmu477814\_mir) and U6 snRNA (001973). qPCR of mRNAs was detected using FastStart SYBR Green Master (04673484001, Roche) and normalized to  $\beta$ -actin in StepOne<sup>™</sup> Real-Time PCR Systems (Applied Biosystems). The sets of primer sequence were ordered from ThermoFisher Scientific in Additional file 1: Table S1.

### **Luciferase assay and transfection**

The 3'-UTR of murine *AMPK $\alpha$*  was PCR amplified using the following primers 5'-TGG TAG CAT AGC ATA ATG GG-3' and 5' -CAA CAG TTT ATA GAG ATA TTC CTC AG-3' and cloned into the pGL3 Luciferase Reporter Vectors (Promega). HEK293T cells were seeded for co-transfection of *AMPK $\alpha$*  3'-UTR plasmid and *miR-148a* mimics (MC10263, ThermoFisher Scientific) or *miVana*<sup>™</sup> miRNA Mimic, Negative Control #1 (4464058, ThermoFisher Scientific). After 48 h of transfections, luciferase assays were detected using the Dual-Luciferase<sup>®</sup> Reporter Assay System (Promega) following the manufacturer's manual.

### **Histological detection**

The adipose tissue pads and liver were dissected from 16-week-old mice, fixed in 4% paraformaldehyde (PFA), and embedded in paraffin. Tissue sections were stained with hematoxylin and eosin (H&E) and imaged using a Nikon ECLIPSE 80i microscope.

### **Statistical analyses**

All experimental data were expressed as mean  $\pm$  standard error (SEM), statistical analysis was performed using student's *t* test, two-way ANOVA in GraphPad Prism 8, and ANCOVA in SPSS. *P* < 0.05 was considered statistically significant (Additional file 2: Table S2.).

## **3. Results**

### **High fat diet induces obesity**

To observe HFD-induced obesity, C57/BL6J mice were divided into two groups and fed with normal chow diet or high fat diet from 6-week-old. Body weight was monitored weekly until 16-week-old age. Interestingly, administration of the high fat diet can significantly increase in body weight compared to chow diet controls starting at 8-week-old age (Fig 1a). The increased body weight was likely due to an increase in fat mass as shown by NMR analysis of body composition at 16 weeks of age (Fig 1b, c). Consistent with increased adiposity, plasma levels of leptin were strongly increased almost fifteen-fold in HFD mice compared to normal chow diet fed mice (Fig 1d). Due to the association of obesity with

diabetes and insulin resistance, we further analyzed the systemic glucose metabolism in HFD fed mice and normal chow diet fed mice. Both random and fasting plasma glucose and insulin levels were elevated in HFD mice (Fig 1e, f). Glucose and insulin tolerance tests (GTT and ITT) showed higher glucose levels in HFD mice in comparison to chow diet fed controls indicating systemic insulin sensitivity was reduced (Figure 1g, h). Lastly, the determination of plasma levels of various hormones including triglyceride, FFA, glycerol and cholesterol were also significantly elevated in the HFD mice (Fig. i-l).

### **Changes in basic metabolic rates in HFD feeding mice**

To understand the factors which may contribute to the increase in body mass and adiposity, we next determined energy metabolism in these animals in HFD animals. Indirect gas calorimetry was used to calculate basic metabolic rates in these animals at 12-week-old age. As shown in Fig. 2, HFD mice exhibited no changes in oxygen consumption, but decreases in carbon dioxide production (Fig. 2b). Energy expenditure was slightly increased in HFD mice (Fig. 2c). These results translate into a decrease in the nutrient partitioning (based on respiratory exchange rate (RER) measured in HFD mice and suggest fat to be the predominant energy source (Fig 2d). Additionally, the spontaneous locomotor activity was reduced in HFD mice (Fig. 2e). Moreover, energy expenditure, when plotted in relation to lean body mass in an ANCOVA, is again increased in HFD mice (Fig. 2f). However, this difference disappears when energy expenditure is plotted in relation to locomotor activity (Fig. 2g). These results suggested that HFD animals of similar lean body mass to controls have increased energy expenditure is directly correlated to the shift in metabolic fuel from carbohydrates in normal chow diet to lipids in high fat diet.

### **High fat diet increases Ago2 and *miR-148a* expression in the adipose tissue**

Recent studies have revealed that Ago2-miRNA-mediated mRNA regulation plays a significant role in the hepatic and adipose energy metabolism of obesity [9]. Due to miRNA dysregulation in the large repertoire of physiological processes of obesity [18], we sought to examine the expression of Ago2-mediated signaling in obese adipose tissue. Western blot analysis indicated an increased Ago2 protein levels in adipose tissue of HFD mice compared to normal chow diet fed control (Fig. 3a). Consistent with increased body fat mass, *Ucp1* expression is reduced in BAT and subcutaneous sWAT of HFD mice (Fig. 3a). Meanwhile, qPCR analysis further indicated increased *Ago2* mRNA in different fat tissues after HFD feeding (Fig. 3b). As *miR-148a* has been involved in the energy metabolism [8], the expression level of *miR-148a* was checked by qPCR. Consistent with the *Ago2*, *miR-148a* expression levels were significantly increased in BAT, sWAT, and eWAT of HFD mice compared to normal chow diet fed control mice (Fig. 3c), these results support the critical role of Ago2 in the expression of *miR-148a*.

### **Ago2 regulates miRNA-mediated targeting of *AMPK $\alpha$***

To elucidate the molecular basis for the role of Ago2 in adipose tissues, we next sought to identify candidate target genes that are involved in the lipid metabolism. We first hypothesized that AMPK $\alpha$  may be subject to Ago2: miRNA-mediated gene regulation in the adipose tissue in light of its prominent role in lipid metabolism as well as its establish role as an energy and metabolic sensor in response to changes

in nutrient and hormone availability [19, 20]. Importantly, *AMPK*'s 3' UTR has been reported to have an *miR-148/152* target site [8]. To establish the direct interaction between *Ago2*, *miR-148a*, and the *AMPK* mRNA, we performed luciferase assays in which *AMPK*'s 3' UTR was cloned into luciferase expression vector. The luciferase activity of each was measured in HEK293 cells. Comparing to control miRNA mimics, *miR-148a* mimics can strongly inhibit the luciferase activity (Fig. 4a). Western blots also indicated a decreased protein level of AMPK $\alpha$  after transfection of *miR-148a* mimics (Fig. 4b). We next measured expression of *AMPK* in different adipose tissues and identified the down-regulation of *AMPK* mRNA after HFD feeding (Fig. 4c). Western blot confirmed a similar decrease in both total AMPK $\alpha$  protein and p-AMPK $\alpha$  in HFD mice compared to normal chow diet control mice (Fig. 4d), which is associated with a decreased AMPK activity represented as the ratio of p-AMPK $\alpha$ /AMPK $\alpha$  in the fat tissues of HFD mice (Fig. 4e). Together, those data indicated that *miR-148a* is involved in suppression of *AMPK* expression in a manner dependent on *Ago2* and a *miR-148a* target site.

### High fat diet causes the lipid accumulation by changing lipid metabolism

To further determine the causes for the increased body weight, we next performed histological analysis in the BAT, ingWAT, eWAT and liver. As expected, hematoxylin and eosin stain revealed a massive lipid accumulation in HFD fed BAT compared to normal chow diet mice (Fig. 5a). Consistent with this observation, gene expression analysis showed HFD increased *Elovl3* expression, which is involved in fat cell elongation, but decreased expression of genes involved in BAT thermogenesis and oxidation (including *Ucp1*, *Cidea*, *Cox8b*) (Fig. 5b). Histological analysis of WAT tissue suggests a lipid hypertrophy in fat cells of HFD mice (Fig. 5c, e), however, expression analysis in eWAT of BAT enriched genes was unaltered in HFD mice (Fig. 5f). Finally, image analysis of liver also shows strongly increased lipid accumulation in liver (Fig. 5g). Consistently, the gene expression of *Cidea* increased significantly in liver (Fig. 5h). Also, the expression of  $\beta$ -oxidation-related genes in mitochondria such as *UCP1*, *Ucp2* and *Cpt1* decreased (Fig. 5h, i). The increased expression of *Elovl3*, *Cpt1* and *Cd36* suggested increased synthesis of fatty acids and triglyceride, and free fatty acid uptake, respectively (Fig. 5h, i). The expression of genes related to *de novo* fatty acids synthesis such as *Fas*, and *ACC1* showed decreased expression (Fig. 5i), which implicated the hepatic lipid accumulation induced by HFD was not caused by the increase of *de novo* fatty acids synthesis, but more likely due to the ectopic lipid deposition triggered by the excessive fat storage in adipose tissue.

## 4. Discussion

Numerous studies have described mechanisms which illustrate the contribution of the miRNA signaling in maintaining the balance between energy intake and expenditure. In the current study, we show that mice feeding with HFD exhibit diet-induced obesity and decreases in glucose homeostasis, insulin sensitivity and energy expenditure rate. Mechanistically, our measurements further show HFD induced obesity resulted in an alteration in expressions of *Ago2*-mediated miRNA signaling in adipose tissues. This causes suppression of miR-148a target gene *AMPK* $\alpha$ , which is an important nutrient and energy sensor in maintaining energy homeostasis. Those results are in line with previous studies showing *Ago2*

and miRNAs are involved adipogenesis [15, 21] and emphasize an important role for Ago2 in regulation of body homeostasis and fat adiposity.

Ago2, as a component of the miRNA-induced silencing complex, has been recently shown to be involved in the metabolic regulation because of its effects on insulin resistant and glucose metabolism [6, 8]. Ago2 shows beneficial impacts on obesity and insulin resistance by promoting pancreatic  $\beta$  cell expansion [6]. Notably, liver Ago2 levels are elevated in the obese mice [7], hepatic Ago2-deficiency improves glucose metabolism in conditions of high-fat diet challenge [8], suggesting that Ago2 signaling might be impaired in different organs during obesity. Our data indicate that Ago2 expression in adipose tissues is increased in diet-induced model of obesity, in consistent with the role of Ago2 in obesity.

Furthermore, recent studies showed that several miRNAs controlled by Ago2 are key regulator of adiposity and involved in biological functions of adipogenesis. For example, *miR-148a* is a key miRNA and its expression gradually increased in the process of controlling human adipose-derived mesenchymal stem cells differentiation into adipocytes through binding to the target gene *WNT1* [15, 21]. Loss of *miR-93* can increase adipose cell differentiation, fat mass and subsequently insulin resistance by targeting *Tbx3* gene [14]. Furthermore, *miR-34a* has been found to be increased which is associated with obesity and inhibit fat cell browning; Downregulation of *miR-34a* can elevate expression of *FGF21* and results in induction of the browning genes *Ucp1*, *Pgc-1*, and *Prdm16* [22]. Consistent with above studies is our observation showing an increase in expression of *miR-148a* in the adipose tissues of HFD fed mice.

A common characteristic of obesity is high circulating lipid levels, partly accounted by impaired insulin-mediated suppression of lipolysis. AMPK $\alpha$ , an important cellular energy sensor, has been implicated in control of whole-body adiposity through regulation of lipolysis [23]. For example, AMPK inhibits lipogenesis in isolated adipocytes via increased ACC phosphorylation in response to AICAR stimulation [24], while enhanced activation of AMPK can promote lipolysis [25]. While knockout of AMPK $\alpha$  in mice caused an increased body weight and fat mass due to the enlarged adipocytes and lipid accumulation in fat cells [26]. Consequently, we speculated that the regulation of adipose tissue by Ago2 is realized through *Ago2-miR-148a-AMPK $\alpha$*  signaling pathway. Obesity induces the increase of Ago2 expression, which enhances the silencing effect of *miR-148a* on *AMPK $\alpha$* , and subsequently reduces the activity of *AMPK $\alpha$* , inhibits the calorie burning ability of adipocytes, and finally leads to lipid accumulation.

## Conclusion

In conclusion, our observations on the Ago2 provide further insight into identifying a specific miRNA signaling which regulate obesity and energy homeostasis in adipose tissue. Improving our understanding of Ago2 in adiposity and lipid metabolism may facilitate mapping of distinct systemic networks to delineate the unique properties of separate cell populations contributing to metabolism. It will be important to further investigate mechanism of how Ago2 and related miRNAs in the progression of diet-induced obesity.

# Abbreviations

ACC1: Acetyl-Coenzyme A carboxylase alpha; ACC2: Acetyl-Coenzyme A carboxylase beta; Ago2: Argonaute 2; BAT: Brown adipose tissue; AMPK $\alpha$ 1: Protein kinase, AMP-activated, alpha 1 catalytic subunit; Cd36: CD36 molecule; Chow: Chow diet; Cidea: Cell death-inducing DNA fragmentation factor, alpha subunit-like effector A; ChREBP: MLX interacting protein-like; Cox8b: Cytochrome c oxidase subunit 8B; Cpt1: Carnitine palmitoyltransferase 1a; EE: Energy expenditure; ELISA: Enzyme-linked immunosorbent assay; Elovl3: Elongation of very long chain fatty acids; eWAT: Epididymal white adipose tissue; Fas: Fatty acid synthase; FFA: Free fat acid; GPAT: Glycerol-3-phosphate acyltransferase, mitochondrial; GTT: Glucose tolerance test; HFD: High-fat diet; HMGCR: 3-hydroxy-3-methylglutaryl-Coenzyme A reductase; ingWAT: Inguinal white adipose tissue; ITT: Insulin tolerance test; LBM: Lean body mass; miRNA: microRNA; RER: Respiratory exchange ratio; Ldlr: Low density lipoprotein receptor; RISC: RNA-induced silencing complex; S14: SPOT14, Thyroid hormone responsive; Srebp1: Sterol regulatory element binding transcription factor 1; sWAT: Subcutaneous white adipose tissue; TD-NMR: Time-domain nuclear magnetic resonance; Ucp1: Uncoupling protein 1; Ucp2: Uncoupling protein 2

# Declarations

## Funding

This work was funded by the National Natural Science Foundation of China (82071326, 81870587), China Scholarship Council (201708410345), Foundation for the University Key Teacher by the Henan Province (2020GGJS148), Key Technologies R&D Program of Henan Province (222102310086), Natural Science Foundation of Henan Province for Distinguished Young Scholars (202300410307), Graduate Research and Innovation Program of Xinxiang Medical University (YJSCX202001Z), College Students' Innovation and Entrepreneurship Training Program (202110472013).

## Availability of data and material

All primary data supporting the findings of this study are available on reasonable request.

## Author's contributions

H.Z., L.Q., X.L., X.H., J.K., Y.L., J.L. and X.Y. contributed to the conception and design of the study, L.Q. and X.Y. wrote the manuscript. All authors approved the final version of this manuscript.

## Ethics approval and consent to participate

Not applicable.

## Consent for publication

Not applicable.

## Competing Interests


The authors declare that they have no competing interests.

## References

1. Blüher M. Obesity: global epidemiology and pathogenesis. *Nat Rev Endocrinol.* 2019; 15: 288–98.
2. Piché M-E, Tchernof A, Després J-P. Obesity Phenotypes, Diabetes, and Cardiovascular Diseases. *Circ Res.* 2020; 126: 1477–500.
3. Zhang AMY, Wellberg EA, Kopp JL, Johnson JD. Hyperinsulinemia in Obesity, Inflammation, and Cancer. *Diabetes Metab J.* 2021; 45: 285–311.
4. Meister G. Argonaute proteins: functional insights and emerging roles. *Nat Rev Genet.* 2013; 14: 447–59.
5. Müller M, Fazi F, Ciaudo C. Argonaute Proteins: From Structure to Function in Development and Pathological Cell Fate Determination. *Front Cell Dev Biol.* 2019; 7: 360.
6. Tattikota SG, Rathjen T, McAnulty SJ, Wessels H-H, Akerman I, van de Bunt M, et al. Argonaute2 mediates compensatory expansion of the pancreatic  $\beta$  cell. *Cell Metab.* 2014; 19: 122–34.
7. Yan X, Wang Z, Bishop CA, Weitkunat K, Feng X, Tarbier M, et al. Control of hepatic gluconeogenesis by Argonaute2. *Mol Metab.* 2018; 18: 15–24.
8. Zhang C, Seo J, Murakami K, Salem ESB, Bernhard E, Borra VJ, et al. Hepatic Ago2-mediated RNA silencing controls energy metabolism linked to AMPK activation and obesity-associated pathophysiology. *Nat Commun.* 2018; 9: 3658.
9. Bhattacharjee J, Borra VJ, Salem ESB, Zhang C, Murakami K, Gill RK, et al. Hepatic Ago2 Regulates PPAR $\alpha$  for Oxidative Metabolism Linked to Glycemic Control in Obesity and Post Bariatric Surgery. *Endocrinology.* 2021; 162: bqab007.
10. Peirce V, Carobbio S, Vidal-Puig A. The different shades of fat. *Nature.* 2014; 510: 76–83.
11. Reilly SM, Saltiel AR. Adapting to obesity with adipose tissue inflammation. *Nat Rev Endocrinol.* 2017; 13: 633–43.
12. Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. *Am J Physiol Cell Physiol.* 2021; 320: C375–91.
13. Wu Y, Zuo J, Zhang Y, Xie Y, Hu F, Chen L, et al. Identification of miR-106b-93 as a negative regulator of brown adipocyte differentiation. *Biochem Biophys Res Commun.* 2013; 438: 575–80.
14. Cioffi M, Vallespinos-Serrano M, Trabulo SM, Fernandez-Marcos PJ, Firment AN, Vazquez BN, et al. MiR-93 Controls Adiposity via Inhibition of Sirt7 and Tbx3. *Cell Rep.* 2015; 12: 1594–605.
15. Shi C, Zhang M, Tong M, Yang L, Pang L, Chen L, et al. miR-148a is Associated with Obesity and Modulates Adipocyte Differentiation of Mesenchymal Stem Cells through Wnt Signaling. *Sci Rep.* 2015; 5: 9930.


16. Peng J, Zhou Y, Deng Z, Zhang H, Wu Y, Song T, et al. miR-221 negatively regulates inflammation and insulin sensitivity in white adipose tissue by repression of sirtuin-1 (SIRT1). *J Cell Biochem.* 2018; 119: 6418–28.
17. Pan Y, Hui X, Hoo RLC, Ye D, Chan CYC, Feng T, et al. Adipocyte-secreted exosomal microRNA-34a inhibits M2 macrophage polarization to promote obesity-induced adipose inflammation. *J Clin Invest.* 2019; 129: 834–49.
18. Zaiou M, El Amri H, Bakillah A. The clinical potential of adipogenesis and obesity-related microRNAs. *Nutr Metab Cardiovasc Dis NMCD.* 2018; 28: 91–111.
19. Yan C, Tian X, Li J, Liu D, Ye D, Xie Z, et al. A High-Fat Diet Attenuates AMPK  $\alpha$ 1 in Adipocytes to Induce Exosome Shedding and Nonalcoholic Fatty Liver Development In Vivo. *Diabetes.* 2021; 70: 577–88.
20. Fullerton MD, Galic S, Marcinko K, Sikkema S, Pulinilkunnil T, Chen Z-P, et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. *Nat Med.* 2013; 19: 1649–54.
21. Price NL, Fernández-Hernando C. miRNA regulation of white and brown adipose tissue differentiation and function. *Biochim Biophys Acta.* 2016; 1861: 2104–10.
22. Fu T, Seok S, Choi S, Huang Z, Suino-Powell K, Xu HE, et al. MicroRNA 34a inhibits beige and brown fat formation in obesity in part by suppressing adipocyte fibroblast growth factor 21 signaling and SIRT1 function. *Mol Cell Biol.* 2014; 34: 4130–42.
23. Garton AJ, Campbell DG, Carling D, Hardie DG, Colbran RJ, Yeaman SJ. Phosphorylation of bovine hormone-sensitive lipase by the AMP-activated protein kinase. A possible antilipolytic mechanism. *Eur J Biochem.* 1989; 179: 249–54.
24. Sullivan JE, Brocklehurst KJ, Marley AE, Carey F, Carling D, Beri RK. Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase. *FEBS Lett.* 1994; 353: 33–6.
25. Yin W, Mu J, Birnbaum MJ. Role of AMP-activated protein kinase in cyclic AMP-dependent lipolysis in 3T3-L1 adipocytes. *J Biol Chem.* 2003; 278: 43074–80.
26. Villena JA, Viollet B, Andreelli F, Kahn A, Vaulont S, Sul HS. Induced adiposity and adipocyte hypertrophy in mice lacking the AMP-activated protein kinase- $\alpha$ 2 subunit. *Diabetes.* 2004; 53: 2242–9.

## Figures



**Figure 1**

**High fat diet results in increased body weight and insulin resistance.** **a**, Body weight curves of HFD fed mice ( $n=12$ ) and normal chow diet fed controls from 6 to 16 weeks of age. **b**, Lean body mass and fat mass in 16-week-old HFD and normal chow diet fed mice ( $n=6-11$ ). **c**, Tissue mass to body weight ratio in HFD and control mice ( $n=6-11$ ). **d**, Plasma leptin measurements in 16-week-old HFD and chow diet controls ( $n=6-10$ ). **e**, **f**, Random and fasted plasma glucose and insulin measurement of HFD and Chow mice at 16-week-old age ( $n=6, 10$ ). **g**, **h**, Glucose measurements during glucose (**g**) and insulin (**h**) tolerance test on 12-week-old HFD and normal chow diet fed mice ( $n=5-8$ ). **i-l**, Plasma triglyceride, free fatty acid (FFA), glycerol and cholesterol measurement on 16-week-old HFD and normal chow diet fed mice ( $n=6-11$ ). Results are presented as mean  $\pm$  SEM.  $*P < 0.05$ ,  $**P < 0.01$  and  $***P < 0.001$ .



**Figure 2**

**High fat diet alters energy metabolism in mice.** **a-e**, Quantification of  $O_2$  production,  $CO_2$  consumption, energy expenditure, RER and locomotor activity, respectively in 16-week-old HFD and Chow mice ( $n=6-7$ ). **f**, Energy expenditure of individual animals plotted against lean body mass from 16-week-old HFD ( $n=6$ ) and normal chow diet fed mice ( $n=7$ ). **g**, Energy expenditure of individual animals plotted against locomotor activity from 16-week-old HFD ( $n=6$ ) and normal chow diet fed mice ( $n=7$ ). Results are presented as mean  $\pm$  SEM. \* $P < 0.05$ , \*\* $P < 0.01$  and \*\*\* $P < 0.001$ .




Figure 3

**Increased expression of Ago2 and miR-148a in fat tissues of HFD mice.** **a**, Western blot analysis of Ago2 and Ucp1 in total lysate from BAT, sWAT, and eWAT of wild type mice on normal chow diet and littermate controls on HFD feeding. **b and c**, qPCR analysis of *Ago2* and *miR-148a* from BAT, sWAT, and eWAT of HFD and Chow mice at 16 weeks old (n=6). Results are presented as mean  $\pm$  SEM. \* $P < 0.05$ , \*\* $P < 0.01$  and \*\*\* $P < 0.001$ .





Figure 4

**Ago2 regulates miRNA-mediated targeting of AMPKα.** **a**, Luciferase assays in HEK293 cells testing direct targeting of AMPKα genes by miR-148a (148a-mimic). **b**, Western blot analysis of AMPKα in HEK293 cells after transfection of *miR-148a* and *control mimic*. **c**, qPCR analysis of *AMPKα1* from BAT, sWAT, and eWAT of HFD (n=6) and Chow (n=6) mice at 16 weeks old. **d**, Western blot analysis of p-AMPKα and AMPKα from BAT, sWAT, and eWAT of HFD and Chow mice at 16 weeks old. **e**, Quantification of p-AMPKα/AMPKα from BAT, sWAT, and eWAT of HFD and Chow mice at 16 weeks old. Results are presented as mean ± SEM. \* $P < 0.05$ , and \*\* $P < 0.01$ .



Zhang et al., 2022  
 Figure 5

Figure 5

**Lipid accumulation in HFD mice.** **a-h**, Haematoxylin and eosin staining of BAT, ingWAT, eWAT and liver and qPCR gene expression analysis from 16-week-old normal chow diet and HFD fed mice (n=6). **i**, qPCR analysis for gene expression from liver of 16-week-old normal chow diet and HFD fed mice (n=6). Results are presented as mean  $\pm$  SEM. \* $P$  < 0.05, \*\* $P$  < 0.01 and \*\*\* $P$  < 0.001.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Additionalfile1.docx](#)
- [Additionalfile2.docx](#)